Search
Paliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalIt has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. … It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Categories: Dopamine D2 Receptor Antagonists, P-glycoprotein inhibitorsProducts: INVEGA SUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 25MG, INVEGASUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 75 MGGlycogen phosphorylase, muscle form
go.drugbank.com/bio_entities/BE0000916TargetHumansAllosteric enzyme that catalyzes the rate-limiting step in glycogen catabolism, the phosphorolytic cleavage of glycogen to produce glucose-1-phosphate, and plays a central role in maintaining cellular
Polypeptides: Glycogen phosphorylase, muscle formGlycogen phosphorylase, brain form
go.drugbank.com/bio_entities/BE0002150TargetHumansGlycogen phosphorylase that regulates glycogen mobilization (PubMed:27402852). Phosphorylase is an important allosteric enzyme in carbohydrate metabolism (PubMed:3346228).
Polypeptides: Glycogen phosphorylase, brain formGlycogen [starch] synthase, muscle
go.drugbank.com/bio_entities/BE0012663TargetHumansGlycogen synthase participates in the glycogen biosynthetic process along with glycogenin and glycogen branching enzyme. … In this context, glycogen synthase transfers the glycosyl residue from UDP-Glc to the non-reducing end of alpha-1,4-glucan
Polypeptides: Glycogen [starch] synthase, muscleSynonyms: Glycogen synthase 1Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalRopinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 b...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REQUIP PD 24 HOUR, REQUIP PD 24 HOUR 2mg Prolonged Release TabletsPheniramine
go.drugbank.com/drugs/DB01620ApprovedPheniramine's use as an anti-allergy medication has largely been supplanted by second-generation antihistamines such as [cetirizine] and [loratadine].
Mixtures: Alahist D, Alahist DMProducts: FENİRAMİN-PF 45,5 MG/2 ML I.M./I.V. ENJEKSİYONLUK ÇÖZELTİ, 5 FLAKONCoagulation factor VII human
go.drugbank.com/drugs/DB13150ApprovedInvestigationalCoagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Products: CONCENTRADO DE FACTOR VIIPrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: RESOLOR ® TABLETAS RECUBIERTAS DE 2 MG, RESOLOR ® TABLETAS RECUBIERTAS DE 1 MGCromoglicic acid
go.drugbank.com/drugs/DB01003ApprovedInvestigationalIt is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.
Products: CROMOGLICATO DE SODIO 2%, CROMOGLICATO DE SODIO AL 2%Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease
smpdb.ca/view/SMP0125790DiseaseGlycogen storage disease type 1A (GSD1A), or von Gierke disease, is caused by a defect in the G6PC gene which codes for Glucose-6-phosphatase. … Glycogen storage disease type 1A causes clinically significant end-organ disease with significant morbidity. Usually it presents in childhood.